Retinoic acid X receptor alpha (RXRα) and Connexin 43 (Cx43) both play a crucial role in cardiogenesis. However, little is known about the interplay mechanism between the RXRα and Cx43. Methods: The activations of retinoic acid response element (RARE) in Cx43 were measured by luciferase transfection assay. Electrophoretic mobility shift assay (EMSA) and chromatin immunoprecipitation (ChIP) was performed to prove that RXRα can directly bind to the RARE sequence. Quantitative real-time polymerase chain reaction (qRT-PCR) and western blotting were used to analyze the RXRα and Cx43 mRNA level and protein level in cells. results: In this study, we confirmed the negative association of the gene expression between the RXRα and Cx43 in the cell level. Interestingly, a functional RARE was detected in the region from −1,426 to −314 base pairs upstream from the transcriptional start site of Cx43. Moreover, we also prove that RXRα can directly bind to this RARE sequence in vitro and in vivo. conclusIons: RXRα negatively regulates the transcription and expression by directly binding to the RARE in the promoter of Cx43. The RARE-like sequence harbored in the Cx43 promoter region may serve as a functional RARE in the retinoic acid (RA) signaling pathway. c ongenital heart disease is the most common birth defect in live neonatal infants, with a prevalence of 8 to 12 per 1,000 live births (1,2). Cardiac development requires a precise and extremely complex series of molecular mechanisms to maintain the proper expression of cardiac transcription factors, and abnormal alterations in these expressions can result in heart defects (3,4). However, the pathogenesis of congenital heart disease is not completely understood.
c ongenital heart disease is the most common birth defect in live neonatal infants, with a prevalence of 8 to 12 per 1,000 live births (1, 2) . Cardiac development requires a precise and extremely complex series of molecular mechanisms to maintain the proper expression of cardiac transcription factors, and abnormal alterations in these expressions can result in heart defects (3, 4) . However, the pathogenesis of congenital heart disease is not completely understood.
Connexin 43 (Cx43), also known as GJA1, is a member of the connexin multi-gene family. In the human adult heart, Cx43 forms intercellular communication channels at the plasma membrane to ensure electrical and metabolic coupling between cells (5, 6) . In addition to its role in adult hearts, Cx43 is also important for normal embryonic heart development. Some investigators have altered the gene dosage of Cx43 in the animal model and found pulmonary outflow tract obstruction or conotruncal heart malformation in mice, confirming the importance of Cx43 in conotruncal heart development (7, 8) . However, an alteration in the Cx43 protein status inducing heart defects in human has not been confirmed (9) . Some studies showed mutations in the Cx43 sequence were not commonly associated with human heart malformation (10) (11) (12) , indicating that the Cx43 sequence defect might not be a major contributor to congenital heart disease; the pathogenic mechanism is likely to be a more complex regulatory pathway.
Retinoid acid (RA) is produced by the metabolism of retinaldehyde from retinoids by retinaldehyde dehydrogenase (RALDH) (13, 14) . RA activates or represses target genes through the activation of two members of the nuclear receptor super family, retinoic acid receptors and retinoid X receptors (RXRs), binding to the retinoic acid response element (RARE) in target genes (14) (15) (16) . In some cancer studies (17) (18) (19) , RA has been found to alter the phosphorylation status of the Cx43 protein.
Only a few studies have demonstrated the regulation relationship between RA and Cx43 in heart development (20) , and the phosphorylation status is not a main cause of heart defects (10). It is very important for us to investigate the mechanism of how RA regulates Cx43 in cardiogenesis. Our previous studies indicated that elevated methylation at the retinoid X receptor α (RXRα) promoter may be responsible for downregulating mRNA expression in the right ventricular outflow tract (RVOT) myocardium of patients with TOF (21), while our another observation in TOF patients found that the expression of Cx43 increased (22) . Thus, we used 9-cis RA (9cRA) to up-regulate endogenous RXRα (23, 24) , which decreased Cx43 expression. We also used shRXRα to repress its expression and found that Cx43 expression increased. Therefore, we hypothesize that RXRα could regulate Cx43 expression, but the precise mechanism remains unknown. We searched further for the Cx43 promoter region and detected a RARE-like construction that was located −424 to −407 base pairs upstream of the transcription start site. There Western blotting analyses indicated that the endogenous RXRα expression increased after 9cRA stimulation and that the Cx43 level decreased as the 9cRA concentration increased (Figure 1, panel a) . However, Cx43 expression was upregulated after shRXRα was used to suppress RXRα and was not influenced by 9cRA (Figure 1, panel b) . A quantitative realtime polymerase chain reaction (qRT-PCR) experiment was performed in HEK293 cells that were treated with different concentrations of 9cRA for 24 h, which showed that the mRNA expression level of Cx43 decreased ~2.6-fold (1 μmol/l 9cRA) and ~3.6-fold (10 μmol/l 9cRA) (P < 0.001; To confirm whether RXRα is located in the nucleus and could regulate Cx43 expression, we performed an immunofluorescence assay with antibodies against RXRα and Cx43. As shown in Figure 3 , the RXRα protein was localized in the nucleus, and An analysis of the promoter region of the Cx43 gene revealed putative RAREs ranging from −424 to −407 base pairs upstream of the transcription start site (TSS). This RARE in the Cx43 promoter was conserved between human, mouse, dog, and elephant (ENSG00000152661; Figure 4 , panel a) (25).
To investigate whether 9cRA could repress Cx43 expression by RXRα binding this putative RARE, we performed a luciferase assay using HEK293, HeLa and HL-1 cells that were cotransfected with the RXRα expression vector and a luciferase vector containing 1426 base pairs of the human Cx43 promoter. In the presence of 9cRA, we observed a significant decrease in the relative luciferase activation of approximately ~2.2-fold in HEK293, ~1.8-fold in HeLa and ~2.4-fold in HL-1 cells, indicating that this region of the Cx43 promoter might harbor a RARE (P < 0.001, HEK293; P < 0.001, HeLa; P < 0.001, HL-1; Figure 4, panel b, left) . Then, a transient cotransfection experiment was performed to examine the effect of mutating this sequence on the promoter activity in the three cell lines. As expected, the luciferase activation was much lower in the mutant RARE (mutRARE) than in the wild-type in the non-RA group (P < 0.001, HEK293; P < 0.001, HeLa; P < 0.001, HL-1; Figure 4 , panel c), and luciferase activation showed no difference in the mutRARE group with 9cRA (P = 0.889, HEK293; P = 0.932, HeLa; P = 0.387, HL-1; Figure 4 , panel b, right). Our results showed that mutRARE lost not only the basal activity of the Cx43 promoter in the non-RA group but also the inhibitory effect of RARE in the presence of 9cRA ( Figure 4, panel b; Figure 4 , panel c). To further confirm the function of the putative RARE, we also transfected pGL3-Cx43-Luc or pGL3-mutCx43-Luc to cells in which RXRα were knocked out by pGreen-shRXRα. In the pGL3-Cx43-Luc group, the relative luciferase activation increased ~1.50-fold in HEK293 cells, ~1.59-fold in HeLa cells and 2.44-fold in HL-1 cells (P < 0.001, HEK293; P < 0.001, HeLa; P < 0.001, HL-1; Figure 4 , panel e, left). The relative luciferase activation was not changed in pGL3-mutCx43-Luc with shRXRα (P = 0.545, HEK293; P = 0.631, HeLa; P = 0.978, HL-1; Figure 4 , panel e, right).
To further localize the putative RARE, we constructed a series of luciferase vectors with truncate promoters to test whether progressively deleting parts of the Cx43 promoter would abolish 9cRA-dependent transactivation. In the non-RA-treated group of three cell lines, the relative luciferase activation decreased significantly in -314-Cx43-Luc and -226-Cx43-Luc compared to that in -1426-Cx43-Luc (the same construction as PGL3-Cx43-Luc) (relative luciferase activation of -314-Cx43-Luc and -226-Cx43-Luc, respectively reduced to ~2.84-fold and ~10.57 in HEK293; ~2.41-fold and ~5.61-fold in HeLa; ~4.41-and 13.45-fold in HL-1; Figure 4 , panel c). When 9cRA was added, the relative luciferase activation reduced only in -1426-Cx43-Luc (P < 0.001, HEK293; P < 0.001, HeLa; P < 0.001, HL-1; Figure 4 , panel b, left); however, 9cRA did not affect the luciferase activation of -314-Cx43-Luc (P = 0.584, HEK293; P = 0.053, HeLa; P = 0.138, HL-1; Figure  4 , panel f, left) and -226-Cx43-Luc (P = 0.837, HEK293; P = 0.879, HeLa; P = 0.638, HL-1; Figure 4 , panel f, right). Our observation suggests that RARE is likely to reside in the region from −1,426 to −314 base pairs upstream from the transcriptional start site.
RXRα Interacts Directly With Cx43 via RARE
To confirm the interaction of RXRα with the RARE in the Cx43 promoter, we performed an electrophoretic mobility shift assay (EMSA). A binding complex was formed between RXRα and the labeled wild-type Cx43 RARE with or without 9cRA ( Figure 5, panel a, Lanes 1 and 2) . However, this binding was not observed with the mutated probe ( Figure 5, panel a,  Lanes 3 and 4) . When a cold RARE-probe was added in addition to the binding reaction, the binding was completely abolished ( Figure 5 , panel a, Lanes 5 and 6). However, the excess mutant RARE-probe failed to block this interaction ( Figure 5 , panel a, Lanes 7 and 8). Furthermore, we performed a shiftwestern assay to clarify the component of RXRα/RARE. The results of the shift-western assay showed that RXRα could bind to Cx43 RARE whether 9cRA existed or not ( Figure 5, panel  b) . Collectively, these data indicate that RXRα specifically binds to the RARE in the Cx43 gene promoter.
The Identification of the RXRα Binding of Cx43 by ChIP Assay
A chromatin immunoprecipitation assay (ChIP) was performed to investigate whether RXRα is able to bind to the Cx43 promoter in vivo. Non-RA and 9cRA-treated HeLa cells were used in the ChIP assay. A specific PCR product was detected when the cells were treated with a specific anti-RXRα antibody, but were not detected when treated with a nonspecific immunoglobulin G control ( Figure 5, panel c) . DNA fragments containing Cx43 RARE sequences were detected in the PCR products ( Figure 5, panel d) . In quantitative real-time PCR, a significant enrichment of RXRα on the Cx43 RARE was observed in both groups (the % input immunoprecipitated with the RXRα antibody and normal IgG was ~2.5 vs. 0.09%, dimethylsulfoxide (DMSO) and ~1.93 vs. 0.08%, 9cRA group ( Figure 5, panel e) . Taken together, our findings indicate that RXRα could bind to the Cx43 RARE directly.
DISCUSSION
Changing the level of Cx43 could induce heart defects (7, 8, 26) , and Cx43 might influence cardiac neural crest cell (CNCC) development and migration (27) (28) (29) ; CNCC is crucial for remodeling the vascular system, conotruncal outflow tract septation and the development of the cardiac conduction system (30) . Consequently, the identification and understanding of the molecular signaling pathways that regulate Cx43 function are important. In the present study, we demonstrated that 9cRA downregulates Cx43 protein and mRNA levels and also demonstrated that this repression is a direct transcriptional effect that is mediated by the binding of RXRα to the Cx43 promoter.
The RA signal plays an essential role in embryogenesis, and numerous RA-response genes have been identified, only a few of which are unequivocally direct targets of the RA-receptor complex (16, 31) . The well-known RA target genes, such as RARβ, CYP26, CRABP-II and some Hox gene family members, RXRα, which is activated by 9-cis retinoic acid (9cRA), can regulate cardiac gene expression (23, 36) . In a previous study, the basal transcriptional activity of an atrial naturietic factor (ANF) gene was repressed in the presence of 9cRA (37) . Similar to our findings, Cx43 was downregulated at both the protein and mRNA levels by increasing endogenous RXRα in HEK293, HeLa, and HL-1 cells. Although RXRα did not increase significantly in high concentration of 9cRA (100 μmol/l), Cx43 still decreased while the ligand existed. We also knocked down RXRα expression in HEK293, HeLa and HL-1 cells to determine the role of RXRα in regulating Cx43. The results showed that Cx43 expression increased whether 9cRA existed or not, indicating that RXRα played a crucial role in 9cRA suppressing Cx43. Taken together, we conclude that liganded RXRα is critical for the observed repressive effect on Cx43 gene expression.
Several studies have suggested that the target gene of the RA signal generally contains two direct-repeat half sites of the consensus sequence AGGTCA that are spaced by one to five base pairs (14, 16, 32, 38) . RXRα homodimers activate transcription in response to 9cRA by binding to direct repeats that are spaced by one base pair (DR1 element) (16, 23, 39 ). An analysis of the Cx43 promoter region revealed a novel putative RARE that is spaced by six base pairs ranging from −1,426 to +1 base pair upstream of the transcription start region. However, Xavier-Neto's review demonstrated that the magic AGGTCA has high affinity but poor specificity (16) . Some other NRs also utilized the RARE with the same spacer models that are used by RXRs/RARs, for example, orphan receptors, vitamin D receptors (VDR) and peroxisome proliferator-activated receptors (PPAR) (32, 39) . Identifying a bona fide RARE is more difficult than a simple inspection. In order to attribute the RARE in Cx43 to a candidate sequence, some observations have been conducted in our study using molecular, biological and biophysical methods and functional approaches. In a ligand-dependent luciferase assay, RARE was located between the −1,426 to −341 base pair position. The constitutively active mutant Cx43 RARE represses the luciferase activity in the absence of the ligand and has no response to the 9cRA. Our findings indicate that RARE in the Cx43 promoter is a functional element. The HeLa cell line, with a high level of retinoic acid receptors (40) , is an ideal cell line for the EMSA and ChIP assay. In the EMSA experiment, the proteins could interact with the Cx43 RARE, and the retarded band was completed after excess unlabeled RARE probe was added. We also designed the labeled mutant probe in this assay, and these mutant probes failed to form a retardation band in the gel. A shift-western assay provided additional evidence that RXRα binds to RARE regardless of whether the cells were treated or not treated with 9cRA. In addition to EMSA, we conducted a ChIP assay to determine the relationship between RXRα and Cx43 in vivo. Consistent with the EMSA results, Cx43 RARE could recruit RXRα. These results suggest that Cx43 RARE is a functional element in the RA signaling pathway and that liganded RXRα could repress Cx43 via this functional RARE.
Gene activation through RARE functions through the RA-dependent recruitment of transcriptional coactivators (41) ; however, the mechanism by which RAREs repress transcription is unclear. Kumar and colleagues (34) suggested an RA-dependent repressive role of the Fgf8 RARE by recruiting PRC2 and the repressive H3K27me3 mark to the vicinity of the Fgf8 RARE in trunk tissue. Whether 9cRA repressed Cx43 via RARE through this similar mechanism or another regulation pathway is unclear. Moreover, our study was limited at the cellular level, and the regulation pathway in heart tissue remains unknown. As a result, additional studies are needed to illustrate the regulation mechanism between RA and Cx43-RARE in animal models or patients.
In conclusion, the RARE-like sequence in the Cx43 promoter region may serve as a functional RARE in the RA signaling pathway. RXRα directly binds to this RARE and regulates the transcription and expression of the Cx43 gene.
METHODS

Plasmid Construction
Report assay. The human Cx43 (hCx43) (ENSG00000152661) promoter sequence spanning 1426 base pairs upstream of the translational start codon and serial truncations of the hCx43 gene promoter were produced by PCR amplification using the specific 5' primers and the same 3' primer ( Table 1) . Then, these sequences were cloned into pGL3 basic (Promega, Madison, WI) using KpnI and XhoI sites to produce the -1426-Cx43-Luc, -314-Cx43-Luc and -226-Cx43-Luc vectors. Site-directed mutagenesis of the hCx43 promoter. The left-half site of hCx43 RARE at positions −422 and −421 was mutated from AGATCA to AGCCCA using the primers in Table 1 . The 1426-base pair hCx43-luciferase plasmid with mutant RARE was produced by overlap PCR with the primer pairs mentioned above. The successful introduction of the mutation was confirmed by sequencing (Shanghai Invitrogen, Shanghai, China). Express vector. The human pTango-RXRα-Flag and pTango-shRXRα expression plasmids were provided by Chengdu Lingdong Technology. The human and mouse pGreen-shRXRA (pGreen-human-shRXRα and pGreen-mouse-shRXRα) lentiviral plasmids were designed on the website (Sigma Life Science Biotools, St. Louis, MO) ( Table 2 ) and cloned into pGreen (Promega) using BamHI and EcoRI sites.
Cell Lines and Culture Conditions
The human embryonic kidney cells (HEK 293 cells), HeLa cells and HL-1 cells were cultured in Dulbecco's modified Eagle medium (Hyclone, Logan, UT) that was supplemented with 10% fetal bovine serum (Gibco BRL, Langley, OK) and penicillin (100 U/ml)-streptomycin (100 µg/ml) and maintained at 37 °C in a 5% CO 2 atmosphere. 
Western Blotting
The cells were harvested and solubilized in radio immunoprecipitation assay lysis buffer (50 mmol/l Tris-HCl, 150 mmol/l NaCl, 1% NP-40, 0.1% sodium dodecyl sulfonate) containing protein inhibitor cocktail (Roche, Basel, Switzerland) and phosphate inhibitor (Roche) on ice. The protein concentrations were determined using the bicinchoninic acid assay (Pierce, Rockford, IL) according to the manufacturer's instructions, with bovine serum albumin as the standard. Then, 10 μg of protein was loaded onto and separated in 10% sodium dodecyl sulfonate-polyacrylamide gels. Nitrocellulose membranes (Whatman, GE Healthcare Life Sciences, Buckinghamshire, UK) were blocked for 1 h at room temperature with phosphate-buffered saline containing 10% nonfat milk. Appropriate primary antibodies were incubated with the membranes, followed by peroxidase-conjugated anti-rabbit antibody (dilution at 1:5,000; Pierce), and visualized by enhanced chemiluminescence (Pierce). The primary antibodies that were used were rabbit polyclonal anti-Cx43 (sc-9059; Santa Cruz Biotechnology) and rabbit monoclonal anti-RXRα (ab125001; Abcam). Anti-GAPDH (21612; Signalway Antibody, Park, MD) was used as a loading control.
RNA Extraction and Quantitative Real-Time PCR
The total RNA was extracted from the cells using the Quick-RNA MicroPrep kit (Zymo Research, Irvine, CA). For each sample, 1 μg of total RNA was used for cDNA synthesis with the PrimeScript RT reagent Kit (Takara Biotechnology, Dalian, China) in a 20-μl reaction mix in accordance with the manufacturer's instructions. The final cDNA product was diluted 10-fold and subsequently used as a template for real-time PCR. Amplification reactions were carried out using the SYBR Premix Ex Taq Kit (Takara Biotechnology) and were performed in triplicate in 384-well-plate format using an Applied Biosystems 7900HT Fast Real-time PCR System (Applied Biosystems, Foster City, CA). The relative quantification of gene expression was calculated using the 2 −ΔΔ Ct method. The β-actin expression levels were used for the normalization of gene expression values. The primers of RXRα and Cx43 for real-time PCR are listed in Table 3 .
Transfection and Luciferase Assay
Transient transactions cells were plated in 48-well plates 24 h before transfection and performed using Lipofectamine 2000 (Invitrogen Life Technologies) and X-tremeGENE HP DNA Transfection Reagent (Roche) according to the manufacturer's instructions. We cotransfected cells with 500 ng of the pGL3-Basic, -1426-Cx43-Luc (pGL3-Cx43-Luc), -1426-Cx43-mutRARE (pGL3-mutCx43-Luc), -314-Cx43-Luc, -226-Cx43-Luc and RXRα expression plasmids or pGreen-shRXRα overnight. The next day, the medium was replaced with fresh medium containing 10 μmol/l 9cRA and incubated for another 24 h. The cells extracts were used for the luciferase activities measurement by the dual luciferase assay system (Promega). pRLRenilla (Promega) was used as a normalized plasmid.
EMSA
Whole HeLa cell extracts were treated with DMSO (control) or 10 μmol/l 9cRA. The concentration of these proteins was measured by the bicinchoninic acid assay (Pierce) using bovine serum albumin as a standard. Biotin-labeled double-stranded oligonucleotide probes containing wild-type and mutant Cx43 RARE sequences were bound to whole-cell extracts. The binding reactions were performed using a Light Shift Chemiluminescent EMSA kit (Pierce) according to the manufacturer's protocols. Then, 1 pmol of biotin-labeled duplex oligonucleotides bearing either the RARE or mutRARE was incubated with 10 μg of whole-cell extracts for 10 min in10× binding buffer mixed with1 μg/μl poly (dI•dC), 50% glycerol and 1% NP-40. In competition studies, 200-to 400-fold molar excesses of unlabeled competitor oligonucleotides was added to the reaction. Then, the reaction mixture was electrophoresed on a native 6% polyacrylamide gel and transferred to a positive nylon membrane (Merck Millipore, Darmstadt, Germany). The membrane was optimally UV-light cross-linked, and detection was performed using stabilized streptavidin-horseradish peroxidase conjugate (Pierce) and photographed by the Fuji film Las3000 Luminescent Image Analyzer (Fuji Life Sciences, Tokyo, Japan). The sequences of synthetic duplex oligonucleotide probes are in Table 4 .
Shift-Western Blotting
The combination of the gel shift and the protein immunoblot (called "shift-western blotting") identifies the individual components of protein-DNA complexes (42) . Western blotting was performed after EMSA. For transfers, stacked membranes were used: the first filter below the gel was a nitrocellulose membrane (Whatman), followed by a nylon membrane (Merck Millipore). All of the filters were wetted 
